Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: Glioblastoma trials

The registry lists 37 Glioblastoma studies with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor. 5 are open to participants now and 10 have results posted.

Early Phase 1 4Phase 1 13Phase 2 17No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• GLAD-KE GLioma Biomarker and Safety Assessment During Dietary Ketone Elevation Subtitle: A Surgical Biomarker Discovery Study of Ketogenic Therapy in Recurrent GliomaNot yet recruitingNCT07852975Not applicable
• Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade GliomasNot yet recruitingNCT07778602Early Phase 1
• Precision Radiotherapy Enabled by Molecular MRIRecruitingNCT07512154Not applicable
• Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM)RecruitingNCT07375992Not applicable
• Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With GlioblastomaRecruitingNCT05083754Phase 1
• Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGGTerminatedNCT03973918Phase 2Results posted
• BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 MutationsCompletedNCT03914742Phase 1/2Results posted
• HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent GlioblastomaCompletedNCT03216499Phase 2Results posted
• Neural Progenitor Cell Sparing Radiation Therapy Plus TemozolomideCompletedNCT01478854Not applicableResults posted
• Low Dose Radiation Therapy for Glioblastoma MultiformeCompletedNCT01466686Phase 2Results posted
• Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00895180Phase 2Results posted
• Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00486603Phase 1/2Results posted
• Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBMCompletedNCT00262730Phase 2Results posted
• Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RTTerminatedNCT00068770Phase 2Results posted
• Biological Therapy and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeTerminatedNCT00052715Phase 2Results posted
• 6 Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Newly Diagnosed MGMT Methylated Glioblastoma (GBM)WithdrawnNCT04926168
• Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade GliomasTerminatedNCT03971734Phase 1
• AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing SurgeryTerminatedNCT03965494Early Phase 1
• Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBMCompletedNCT03961971Phase 1
• Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of GlioblastomaTerminatedNCT03707457Phase 1
• A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent GliomasTerminatedNCT03593993
• 5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma MultiformeCompletedNCT03291990Early Phase 1
• Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)CompletedNCT02658981Phase 1
• Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain TumorsCompletedNCT02644291Phase 1
• A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade GliomaCompletedNCT02490930Early Phase 1
• Subventricular Zone (SVZ) and Temozolomide in Glioblastoma MultiformeActive, not recruitingNCT02177578Phase 2
• Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade GliomasCompletedNCT01653834Not applicable
• ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00770471Phase 1
• Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00390403Phase 1
• Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma MultiformeTerminatedNCT00238277Phase 2
• Gefitinib in Treating Patients With Recurrent or Progressive CNS TumorsCompletedNCT00025675Phase 2
• Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or MeningiomaCompletedNCT00010049Phase 1/2
• Gadolinium Texaphyrin Plus Radiation Therapy in Treating Patients With Supratentorial Glioblastoma MultiformeCompletedNCT00006452Phase 1
• Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain TumorCompletedNCT00006358Phase 2
• Pyrazoloacridine Followed by Radiation Therapy in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma MultiformeCompletedNCT00006355Phase 1/2
• Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00004073Phase 2
• Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With GlioblastomaCompletedNCT00003751Phase 2